← All trials
NCT04495322
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2020
- Primary completion
- Oct 31, 2020
- Completion date
- Oct 31, 2020
- First posted
- Jul 31, 2020
- Last posted
- Aug 11, 2020
- Enrollment
- 66
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- TaiGen Biotechnology Co., Ltd.Lead sponsor
- Central South UniversityOverall official - principal investigator
- R&G Pharma Studies Co.,Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.